Evidence map›Paper›PMID 38455644›Full record

ArticleHealth science reports2024

Efficacy and tolerability of

Tony A Shindano, Manix I Masimango, Antoine S Kishabongo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Health science reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Efficacy and tolerability ofHealth science reports · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Tony A ShindanoDepartment of Internal Medicine Hôpital Provincial Général de Référence de Bukavu (HPGRB) Bukavu Democratic Republic of the Congo.ORCID 0000-0002-4473-8088
Manix I MasimangoDepartment of Internal Medicine Hôpital Provincial Général de Référence de Bukavu (HPGRB) Bukavu Democratic Republic of the Congo.
Antoine S KishabongoFaculty of Medicine Université Catholique de Bukavu (UCB) Bukavu Democratic Republic of the Congo.
Université Officielle de Bukavu · CDUniversity of Kindu · CD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Treating Methods: The study enrolled patients with evidence of Results: A total of 179 patients were enrolled. The eradication rate was 79.2% and 80.5% with the OAC-10 and OAC-14 regimen, respectively ( Conclusion: The classic 10-days triple therapy seems to be as effective as the 14-days regimen while having in addition a good tolerance. Apart from cost issues, the bismuth-based therapy seems to be a very good alternative in case of first-line treatment failure.

Indexed as

Democratic Republic of Congoeradication therapiesH. pyloriinflammation

Identifiers

PMID38455644
PMCPMC10918698
OpenAlexW4392552987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.